DRL's revenues rose 6.8% YoY to Rs 37.6 bn (lower our estimates of Rs 40.3 bn) due to better performance of US, India and Europe in global Generics and moderate growth in PSAI segment. Gross margins increased by 180bps YoY to 61.1% in Q1FY16 (higher than our estimates of 56%) on account favorable currency impact.